Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray drying technique.

Ha ES, Baek IH, Cho W, Hwang SJ, Kim MS.

Chem Pharm Bull (Tokyo). 2014;62(6):545-51.

2.

Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs.

Kim MS.

Artif Cells Nanomed Biotechnol. 2013 Dec;41(6):363-7. doi: 10.3109/21691401.2012.762369. Epub 2013 Jan 22.

PMID:
23336707
3.

Oral absorption of atorvastatin solid dispersion based on cellulose or pyrrolidone derivative polymers.

Kim MS, Kim JS, Cho W, Park HJ, Hwang SJ.

Int J Biol Macromol. 2013 Aug;59:138-42. doi: 10.1016/j.ijbiomac.2013.03.068. Epub 2013 Apr 6.

PMID:
23567288
4.

Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process.

Kim JS, Kim MS, Park HJ, Jin SJ, Lee S, Hwang SJ.

Int J Pharm. 2008 Jul 9;359(1-2):211-9. doi: 10.1016/j.ijpharm.2008.04.006. Epub 2008 Apr 12.

PMID:
18501538
5.
6.

Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.

Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RH, Hwang SJ.

Eur J Pharm Biopharm. 2008 Jun;69(2):454-65. doi: 10.1016/j.ejpb.2008.01.007. Epub 2008 Jan 18.

PMID:
18359211
7.

Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation.

Khan FN, Dehghan MH.

AAPS PharmSciTech. 2011 Dec;12(4):1077-86. doi: 10.1208/s12249-011-9673-3. Epub 2011 Aug 31.

8.

Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium.

Maurya D, Belgamwar V, Tekade A.

J Pharm Pharmacol. 2010 Nov;62(11):1599-606. doi: 10.1111/j.2042-7158.2010.01187.x.

PMID:
21039544
9.

[Preparation and evaluation of self-microemulsifying drug delivery systems containing atorvastatin].

Shen HR, Li ZD, Zhong MK.

Yao Xue Xue Bao. 2005 Nov;40(11):982-7. Chinese.

PMID:
16499080
10.

Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS).

Kadu PJ, Kushare SS, Thacker DD, Gattani SG.

Pharm Dev Technol. 2011 Feb;16(1):65-74. doi: 10.3109/10837450903499333. Epub 2010 Jan 20.

PMID:
20088679
11.

Characterization and Pharmacokinetic Study of Aprepitant Solid Dispersions with Soluplus®.

Liu J, Zou M, Piao H, Liu Y, Tang B, Gao Y, Ma N, Cheng G.

Molecules. 2015 Jun 19;20(6):11345-56. doi: 10.3390/molecules200611345.

12.

Soluplus(®) based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation.

Lian X, Dong J, Zhang J, Teng Y, Lin Q, Fu Y, Gong T.

Int J Pharm. 2014 Dec 30;477(1-2):399-407. doi: 10.1016/j.ijpharm.2014.10.055. Epub 2014 Oct 29.

PMID:
25445521
13.

Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan.

Lee JY, Kang WS, Piao J, Yoon IS, Kim DD, Cho HJ.

Drug Des Devel Ther. 2015 May 22;9:2745-56. doi: 10.2147/DDDT.S84070. eCollection 2015.

14.

Preparation, characterization and in vitro intestinal absorption of a dry emulsion formulation containing atorvastatin calcium.

Yin YM, Cui FD, Kim JS, Choi MK, Choi BC, Chung SJ, Shim CK, Kim DD.

Drug Deliv. 2009 Jan;16(1):30-6. doi: 10.1080/10717540802481380.

PMID:
19555306
15.

Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo.

Linn M, Collnot EM, Djuric D, Hempel K, Fabian E, Kolter K, Lehr CM.

Eur J Pharm Sci. 2012 Feb 14;45(3):336-43. doi: 10.1016/j.ejps.2011.11.025. Epub 2011 Dec 8.

PMID:
22172603
16.

Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® e.

Cho Y, Ha ES, Baek IH, Kim MS, Cho CW, Hwang SJ.

Molecules. 2015 May 25;20(6):9496-509. doi: 10.3390/molecules20069496.

17.

Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties.

Shayanfar A, Ghavimi H, Hamishekar H, Jouyban A.

J Pharm Pharm Sci. 2013;16(4):577-87.

18.

Spray-dried solid dispersions of nifedipine and vinylcaprolactam/vinylacetate/PEG₆₀₀₀ for compacted oral formulations.

Soulairol I, Tarlier N, Bataille B, Cacciaguerra T, Sharkawi T.

Int J Pharm. 2015 Mar 15;481(1-2):140-7. doi: 10.1016/j.ijpharm.2015.01.012. Epub 2015 Jan 8.

PMID:
25579869
19.

The use of inorganic salts to improve the dissolution characteristics of tablets containing Soluplus®-based solid dispersions.

Hughey JR, Keen JM, Miller DA, Kolter K, Langley N, McGinity JW.

Eur J Pharm Sci. 2013 Mar 12;48(4-5):758-66. doi: 10.1016/j.ejps.2013.01.004. Epub 2013 Jan 21.

PMID:
23348153
20.
Items per page

Supplemental Content

Write to the Help Desk